SUMMARY QUARTERLY INFORMATION (UNAUDITED) - Summary Quarterly Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Jun. 30, 2015	Jun. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 2,757.2	$ 2,786.8	$ 2,732.4	$ 2,170.1	$ 2,235.4	$ 2,043.3	$ 2,041.1	$ 1,886.2	$ 4,902.5	$ 3,927.3	$ 7,689.3	$ 5,970.6	$ 10,446.5	$ 8,206.0	$ 5,769.6
Expenses	2,590.1	2,339.0	2,390.9	1,599.1	1,618.0	1,371.7	1,686.0	1,529.6	3,990.0	3,215.6	6,329.0	4,587.3	8,919.1	6,205.3	6,179.1
Operating income (loss)	167.1	447.8	341.5	571.0	617.4	671.6	355.1	356.6	912.5	711.7	1,360.3	1,383.3	1,527.4	2,000.7	(409.5)
Net (loss) income attributable to Valeant Pharmaceuticals International, Inc.	$ (385.9)	$ 49.5	$ (53.0)	$ 97.7	$ 512.5	$ 265.0	$ 125.8	$ (22.6)	$ 44.7	$ 103.2	$ 94.2	$ 368.2	$ (291.7)	$ 880.7	$ (866.1)
Earnings per share, basic (in dollars per share)	$ (1.12)	$ 0.14	$ (0.15)	$ 0.29	$ 1.53	$ 0.79	$ 0.38	$ (0.07)	$ 0.13	$ 0.31	$ 0.28	$ 1.10	$ (0.85)	$ 2.63	$ (2.70)
Earnings per share, diluted (in dollars per share)	$ (1.12)	$ 0.14	$ (0.15)	$ 0.28	$ 1.50	$ 0.78	$ 0.37	$ (0.07)	$ 0.13	$ 0.30	$ 0.27	$ 1.08	$ (0.85)	$ 2.58	$ (2.70)
Net cash provided by operating activities	$ 562.3	$ 736.5	$ 410.5	$ 491.1	$ 815.7	$ 618.7	$ 376.0	$ 484.3	$ 901.6	$ 860.3	$ 1,638.1	$ 1,479.0	$ 2,200.4	$ 2,294.7	$ 1,042.0